Other News To Note
Exelixis Inc., of South San Francisco, said the European Medicines Agency accepted for review the marketing authorization application for Cometriq (cabozantinib) for the proposed indication of progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.